MAIA Biotechnology Hits Enrollment Goals in Lung Cancer Trials
MAIA Biotechnology has completed enrollment in one lung cancer study phase and is 65% toward its 2026 target in a pivotal Phase 3 trial.
MAIA Biotechnology has announced back-to-back patient enrollment milestones across two active clinical trials targeting non-small cell lung cancer, signaling steady progress in its THIO drug development program.
The company confirmed that enrollment in Part C of its THIO-101 Phase 2 study is now complete, a benchmark that clears the way for data collection and analysis from that cohort. Completing enrollment in a mid-stage trial is a prerequisite before efficacy results can be meaningfully assessed.
Read more Hilco Real Estate Seeks Buyers for Detroit Rail-Served Industrial Sites →
Separately, MAIA reported that its pivotal THIO-104 Phase 3 study has reached 65 percent of its patient enrollment target for 2026. Phase 3 trials represent the final and most consequential stage of clinical testing before a company can seek regulatory approval, making enrollment pace a closely watched indicator of a program's momentum.
Non-small cell lung cancer accounts for the large majority of all lung cancer diagnoses and remains one of oncology's most active areas for new drug development. MAIA's THIO compound is the focus of both trials, positioning the biotechnology firm to generate a body of clinical evidence across multiple study phases in parallel.
The dual milestones suggest the company is on track to advance its development timeline, though clinical outcomes from both studies have yet to be disclosed. Continue reading at GlobeNewswire - Industry News on Financial Services.
